Login to Your Account



Fear not: Sofinnova backs 'Dauntless' approach to drug development

By Marie Powers
News Editor

Tuesday, July 21, 2015
Dauntless Pharmaceuticals Inc. had a smooth initial take-off, fueled by a $12 million series A supporting a single asset, and that's just the way the San Diego-based company and backer Sofinnova Ventures plan to keep rolling off the runway.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription